Thomson Reuters Innovation Awards 2010 – India
November 12, 2010
Hall Mantra, The Park, 15 Parliament Street, New Delhi 110 001, India


Asia Pacific Pharma Companies Turning to High-Risk, High-Reward Drug Development, According to New Report from Thomson Reuters
PRESS RELEASE November 3, 2010

The Conference of Italian University Rectors Chooses Web of Knowledge from Thomson Reuters for 72 of its Universities
PRESS RELEASE October 7, 2010


Confederation of Indian Industry (CII)

The Confederation of Indian Industry (CII) works to create and sustain an environment conducive to the growth of industry in India, partnering industry and government alike through advisory and consultative processes. Learn More

India Innovation Awards 2010

Thomson Reuters Innovation Awards 2010

Since 2007, Thomson Reuters, a leading provider of intelligent information to the worldwide research and business communities, has been presenting the Thomson Reuters Innovation Award to recognize innovation and entrepreneurship in India. The award recognizes the most innovative academic institutions and commercial enterprises headquartered in India for their spirit of innovation in R&D as it relates to all aspects of patent publications in India.

In previous years, potential award winners were selected from small and medium-sized enterprises headquartered in India. For 2010, all enterprises headquartered in India are included for consideration for the Thomson Reuters Innovation Award 2010.

The award winners are decided by analyzing their innovation through patented technology as recorded in Thomson Reuters patent information services. Criteria for award include the number of patents, the efficiency of innovation and the impact of innovation as measured by patent citations.

 In addition, this year, four awards are presented across four different industrial sectors: Pharma Corporate, Pharma Academic, Hi-Tech Corporate and Hi-Tech Academic.

Previous award winners are omitted from this analysis.


Program Agenda

Time Activities Speaker
06:30 PM Guest Registration — Tea/Coffee & Snacks Served  
07:00–07:05 PM
(05 mins)
Welcome Remarks Mr. Anjan Das
Senior Director
Confederation of Indian Industry
07:05–07:15 PM
(10 mins)
Thomson Reuters — Accelerating Research and Innovation Mr. Keith MacGregor
Executive Vice President, Scientific & Scholarly Research
Healthcare & Science
Thomson Reuters
07:15–07:25 PM
(10 mins)
Special Address Mr. Ajai Chowdhry
HCL Infosystems Limited
07:25–07:40 PM
(15 mins)
Innovation Awards Methodology Mr. Bob Stembridge
Manager — Customer Relations
Thomson Reuters
07:40–07:50 PM
(10 mins)
Presentation Ceremony:
Thomson Reuters Innovation Awards 2010 — India
Mr. Sam Pitroda
Advisor to the Prime Minister on Public Information,
Infrastructure & Innovation
07:50–08:00 PM
(10 mins)
Keynote Address
Mr. Sam Pitroda
Advisor to the Prime Minister on Public Information, Infrastructure & Innovation
08:00–08:10 PM
(10 mins)
Closing Remarks Mr. Woei Fuh Wong
Managing Director — South Asia & South-east Asia
Healthcare & Science
Thomson Reuters
08:10–08:15 PM
(05 mins)
Group Photography of Presenters and Awardees on Stage  
08:15 PM Dinner and Networking  

Hi-Tech Corporate: Bharat Heavy Electricals Limited

BHEL is the largest engineering and manufacturing enterprise in India in the energy-related/infrastructure sector, today. BHEL was established more than 40 years ago, ushering in the indigenous Heavy Electrical Equipment industry in India - a dream that has been more than realized with a well-recognized track record of performance. The company has been earning profits continuously since 1971-72 and paying dividends since 1976-77. 

BHEL manufactures over 180 products under 30 major product groups and caters to core sectors of the Indian Economy viz., Power Generation & Transmission, Industry, Transportation, Renewable Energy, etc. The wide network of BHEL's 14 manufacturing divisions, four Power Sector regional centres, over 100 project sites, eight service centres, 18 regional offices and one subsidiary enables the Company to promptly serve its customers and provide them with suitable products, systems and services —- efficiently and at competitive prices. The high level of quality & reliability of its products is due to the emphasis on design, engineering and manufacturing to international standards by acquiring and adapting some of the best technologies from leading companies in the world, together with technologies developed in its own R&D centres

BHEL has acquired certifications to Quality Management Systems (ISO 9001), Environmental Management Systems (ISO 14001) and Occupational Health & Safety Management Systems (OHSAS 18001) and is also well on its journey towards Total Quality Management

Hi-Tech Academic: Council of Scientific and Industrial Research

The Council of Scientific & Industrial Research (CSIR) — the premier industrial R&D organization in India was constituted in 1942 by a resolution of the then Central Legislative Assembly. It is an autonomous body registered under the Registration of Societies Act of 1860.CSIR aims to provide industrial competitiveness, social welfare, strong S&T base for strategic sectors and advancement of fundamental knowledge.

The Strategic Road Map designed for CSIR as it stepped into the new Millennium envisaged:

  • Re-engineering the organisational structure;
  • Linking research to marketspace;
  • Mobilising and Optimising the resource base;
  • Creating an enabling infrastructure; and
  • Investing in high quality science that will be the harbinger of future technologies.

Interestingly , the Government of India has also announced a new Science and Technology Policy 2003 in the early years of the new century. It  presents  Science and Technology with a human face and emphasizes realities such as facing open, global competition; need for examining social, economic and environmental consequences of S&T; and, aggressive international benchmarking and innovation. It advocates strong support for basic research. It emphasizes manpower build-up and retention as important challenges. It advocates dynamism in S&T governance, through the participation of scientists and technologies.

Today CSIR is recognised as one of the world's largest publicly funded R&D organisations having linkages to academia, R&D organisations and industry. CSIR's 37 laboratories not only knit India into a giant network that impacts and add quality to the life of each and every Indian but CSIR is also party to the prestigious Global Research Alliance with the objective of applying global knowledge pool for global good through global funding. CSIR's R&D portfolio embraces areas as diverse as Aerospace, Biotechnology, Chemicals...indeed, almost the ABC-Z of Indian Science!

Pharma Corporate: Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited (Ranbaxy), India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries.

In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing.

Ranbaxy's mission is 'To become a Research-based International Pharmaceutical Company'. The Company is driven by its vision to 'Achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets'. 

Ranbaxy was incorporated in 1961 and went public in 1973. For the year 2009, the Company recorded Global Sales of US $ 1519 Mn. The Company has a balanced mix of revenues from emerging and developed markets that contribute 54% and 39% respectively. In 2009, North America, the Company's largest market contributed sales of US $ 397 Mn, followed by Europe garnering US $ 269 Mn and Asia clocking sales of around US $ 441 Mn.

Pharma Academic: National Institute of Immunology

The National Institute of Immunology (NII) is an autonomous institution supported by the Department of Biotechnology, Government of India. The Institute is committed to advanced research addressing the basic mechanisms involved in body's defence, host-pathogen interactions and related areas with a view to contribute to the creation of an internationally competitive intellectual knowledge base as a sustainable source of innovative futuristic modalities of potential use in health care.




The basic measure of innovation of entities is to measure the volume of patents to each entity and rank them according to these volumes. It is a provision of patenting that an individual invention can be registered in many countries for patent protection so that one invention can give rise to many patents. Counting patent documents would give rise to much double counting and is not useful for measuring the true volume of innovation. In order to provide a true comparison of innovation, it is necessary to count the number of inventions per entity, rather than the number of individual patents.


An assessment of the impact of an organization's innovation can be made by considering later published inventions which cite the earlier work of the organization being assessed. Since those organizations with a greater number of published inventions have a greater likelihood of being cited, the number of citations is divided by the total number of inventions to produce a normalized measure of citation impact.


To assess the efficiency of research, a suitable approach is to determine the R&D expenditure for the latest financial period and together with the number of inventions patented by the organization to determine the ratio of inventions per million Rupees — the larger the ratio the more efficient the use of R&D expenditure in producing innovation.

Determining the effectiveness of research is a matter of analyzing the patent portfolio of an organization to identify the main areas of technology in which the organization is focusing efforts, and then to compare the number of patents the organization has in a particular technology area with the total number of patents in that technology area to assess how important their holdings are in that area. Adjusting for R&D expenditure produces a normalized measure of effectiveness that can be used to rank organizations for this facet of innovation.


An effective measure of productivity of R&D is to consider the total number of inventions patented by an organization compared to the number of employees in the organization producing that innovation.


Domestic focus of innovation can be assessed by considering the number of national patents in an organization's portfolio as a ratio of the total number of patents. In this way, a measure of how much an organization focuses on the national compared to the international market can be determined.


The international scope of an organization's innovation can be assessed by considering the number of different countries in which their innovation has been filed. This provides a measure of the international competitiveness of the organization.

Downloads & Media

Downloads & Media Coverage

In the News

To View the Photos Click Here

Intelligent Information for Life

Discover life-changing research and innovation from around the globe.